Pharmaceutical Development at Biothera and Daniel K Conners quest to Cure Cancer
Daniel K. Conners started what would become one of the most important cancer research companies of our time in the basement of his Minnesota home during the mid 1990s.
The entirely new cancer treatment envisioned by Conners so long ago is still being tested in the clinic, but the initial results are attracting serious attention from leading oncologists and pharmaceutical firms. This targeted immunotherapy drug works synergistically with monoclonal antibodies to take on innate immune cells with the goal of killing cancer.
Carbohydrate Bio-technology (the work of Daniel K Conners firm at Biothera) has numerous applications for improving the outcomes for serious cancer patients. We are very excited to be on the leading edge of cancer R&D " Daniel K Conners.
In addition to developing cancer drugs, Biothera (led by Conners) has an immune health ingredient business based on the same technology platform. It manufactures and markets food-grade (non-pharmaceutical) ingredients for foods, beverages, dietary supplements, cosmetics and animal nutrition. This is a growing business with tremendous opportunities to deliver our immune-enhancing technologies in every day products, said Conners.
Biotheras intellectual property includes more than 40 U.S. patents and patents pending, plus additional patent filings in more than 20 other countries. Currently, with Conners at the helm, the company has more than 50 employees, with over half focused on the research and development of the companys technology platform in the companys labs at its headquarters in Eagan, Minnesota.
Biopolymer Engineering, Inc was founded by Daniel K Conners in 1997 and later renamed Biothera. Biothera now focuses on the manufacturing and improvement of innate complex carbohydrates. Bioploymer Engineering was recognized as a principal in the purification, characterization and production of a variety of carbohydrates. However, Biotheras platform technology carbohydrate predates the company.
According to Conners, researchers at various universities for decades have studied certain carbohydrates in fungi, cereals and bacteria and have identified a link between these polysaccharides and immune activity. But prior to Biothera, no one had successfully delineated the specific mechanism of action these carbohydrates use to effect immune function. - 17274
The entirely new cancer treatment envisioned by Conners so long ago is still being tested in the clinic, but the initial results are attracting serious attention from leading oncologists and pharmaceutical firms. This targeted immunotherapy drug works synergistically with monoclonal antibodies to take on innate immune cells with the goal of killing cancer.
Carbohydrate Bio-technology (the work of Daniel K Conners firm at Biothera) has numerous applications for improving the outcomes for serious cancer patients. We are very excited to be on the leading edge of cancer R&D " Daniel K Conners.
In addition to developing cancer drugs, Biothera (led by Conners) has an immune health ingredient business based on the same technology platform. It manufactures and markets food-grade (non-pharmaceutical) ingredients for foods, beverages, dietary supplements, cosmetics and animal nutrition. This is a growing business with tremendous opportunities to deliver our immune-enhancing technologies in every day products, said Conners.
Biotheras intellectual property includes more than 40 U.S. patents and patents pending, plus additional patent filings in more than 20 other countries. Currently, with Conners at the helm, the company has more than 50 employees, with over half focused on the research and development of the companys technology platform in the companys labs at its headquarters in Eagan, Minnesota.
Biopolymer Engineering, Inc was founded by Daniel K Conners in 1997 and later renamed Biothera. Biothera now focuses on the manufacturing and improvement of innate complex carbohydrates. Bioploymer Engineering was recognized as a principal in the purification, characterization and production of a variety of carbohydrates. However, Biotheras platform technology carbohydrate predates the company.
According to Conners, researchers at various universities for decades have studied certain carbohydrates in fungi, cereals and bacteria and have identified a link between these polysaccharides and immune activity. But prior to Biothera, no one had successfully delineated the specific mechanism of action these carbohydrates use to effect immune function. - 17274
About the Author:
Uncover the Minnesotan push to Kill Disease at the Disease Technology Questions & Answers with Daniel K Conners web site. Daniel K Conners Professional Bio and Information is also available at Biothera and Daniel K Conners
posted by X - Men at
7:59 PM
0 Comments:
Post a Comment
Subscribe to Post Comments [Atom]
<< Home